SCHEMBL10277550

SCHEMBL10277550

O=Cc1nc2c3ncccc3ccn2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.42
KDM4E B2RXH2 5/20 0.40
HSP90AA1 P07900 2/20 0.40
MMP2 P08253 2/20 0.40
TSHR P16473 2/20 0.40
MAPT P10636 2/20 0.40
ALOX15 P16050 2/20 0.40
HTT P42858 2/20 0.40
GMNN O75496 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MMP9 P14780 1/20 0.40
NFKB1 P19838 1/20 0.40
MMP8 P22894 1/20 0.40
CCR1 P32246 1/20 0.40
THPO P40225 1/20 0.40
MTOR P42345 1/20 0.40
MMP13 P45452 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10277462 0.78 PDE10A (0.50) ERN1KDM4EHSP90AA1MAPTLMNA
SCHEMBL7506327 0.75 RAB9A (0.43) KDM4EMAPTHTTLMNATP53
SCHEMBL7506337 0.75 RAB9A (0.43) KDM4EMAPTHTTLMNATP53
SCHEMBL15023640 0.74 RAB9A (0.39) KDM4EHSP90AA1MMP2TSHRMAPT
SCHEMBL15023643 0.74 RAB9A (0.39) KDM4EHSP90AA1MMP2TSHRMAPT
SCHEMBL7509162 0.73 PDE10A (0.41) KDM4EHSP90AA1MMP2TSHRMAPT
SCHEMBL10277525 0.73 PDE10A (0.41) KDM4EHSP90AA1MMP2TSHRMAPT
SCHEMBL3988339 0.67 RAB9A (0.42) KDM4ETSHRMAPTLMNATP53
SCHEMBL18922382 0.65 LMNA (0.50) KDM4EHSP90AA1MMP2TSHRMAPT
SCHEMBL1369794 0.65 LMNA (0.50) KDM4EHSP90AA1MMP2TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10570156-B2 Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2020-02-25 US disclosed
US-10570156-B2 Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2020-02-25 US disclosed
EP-3210984-B1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2019-06-19 EP disclosed
EP-3210984-B1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2019-06-19 EP disclosed
US-20180072759-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2018-03-15 US disclosed
US-20180072759-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2018-03-15 US disclosed
US-20180072759-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2018-03-15 US disclosed
US-9856274-B2 Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2018-01-02 US disclosed
US-9856274-B2 Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2018-01-02 US disclosed
EP-3210984-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2017-08-30 EP disclosed
US-20140288062-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2014-09-25 US disclosed
US-20140288062-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2014-09-25 US disclosed
US-8765760-B2 [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases SUNOVION PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765760-B2 [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases SUNOVION PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765760-B2 [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases SUNOVION PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
EP-2663565-A2 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2013-11-20 EP disclosed
WO-2012096929-A2 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-07-19 WO disclosed
US-20120178748-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-07-12 US disclosed
US-20120178748-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-07-12 US disclosed
US-20120178748-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178748-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GPR119, NLN ERN1 3825/4885KDM4E 969/4885HSP90AA1 1987/4885
US-20180072759-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GPR119, NLN ERN1 3825/4885KDM4E 969/4885HSP90AA1 1987/4885
US-10570156-B2 Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors PDE3A, PDE2A, PDE5A ERN1 1680/4885KDM4E 1225/4885HSP90AA1 2497/4885
US-20140288062-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GPR119, NLN ERN1 3825/4885KDM4E 969/4885HSP90AA1 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.